Peptides Mimicking the SHBG Function

Endolipid is developing applications in NASH and Cellulite

With the support of:

Ministerio de Ciencia e Innovación - Financiado por la Unión Europea
Vall d'Hebron Recerca
fondo slider
fondo slider
fondo slider
fondo slider
fondo slider
We invite you to participate in moving the NASH peptide closer to the patients
Invest in the NASH peptide
fondo slider
Preclinical results with the NASH peptide show a notable effect in the major pathophysiological causes of the disease, including fibrosis.
Go to the results
fondo slider
Endolipid and Nanovex join forces to develop and commercialize the cellulite peptide.
Press release
fondo slider
Endolipid receives a grant from EU Next Generation Funds to develop the NASH peptide.
logo MICINN
previous arrow
next arrow

The Team

Albert Palomer, PhD CEO

Albert Palomer,
PhD CEO

Senior Executive and Development Consultant / Former CEO ABAC Therapeutics and Head of Med Chemistry at Ferrer and Menarini / Boards member and advisor to start-ups in Spain, Belgium, and S Africa / Co-developer of the NSAID analgesic Enantyum® and the quinolone antibiotic Ozanex®.

Ferrer - ABAC
David M Selva, PhD CSO

David M. Selva,
PhD CSO

Board Member and Scientific Leader / Worldwide expert and KOL on SHBG / Extensive experience on molecular mechanisms regulating SHBG and its role in human disease development / More than 30 papers published in top international journals.

Vall d'Hebron Institut de Recerca
Rafael Simó, MD, Prof CMO

Rafael Simó, MD, Prof
CMO

Head of Endocrinology and Nutrition Department / Deputy Director of Clinical Research at Campus Vall d’Hebron / Professor of Medicine & Endocrinology. Universitat Autònoma de Barcelona / President of the European Association for the Study of Diabetes- Eye Complications.

Vall d'Hebron Institut de Recerca
Agustí Soler CFO

Agustí Soler,
CFO

Financial officer in several start-up companies Cority, Aortix, Endolipid, etc Finance and tax consultant at the FI-Ready Group of Companies.

Fiboost

Anna Alvarez, PhD
In vivo models

Laura Brianso, PhD
In vitro models

Pablo Gabriel,
PhD Student

Lorena Ramos,
Lab Technician


Endolipid Therapeutics

Who are we?

Science meets Business
Team

Team combining basic and clinical research with management in biotech/pharma

Vall d'Hebron Recerca
Science

After basic research at VHIR, the spin-off was created in April 2021

Genesis Ventures
Support

Supported by GENESIS Ventures

Nanovex
Partnering

Peptide nanoformulation for long-lasting and targeted drug delivery

What do we do?

How do we do it?

Peptide for NASH
Peptide for NASH

Peptides EDL3D and EDL6D for celluite and NASH applications

Cream Licensed 2023
Peptide for Cellulite

(Ac-EDL67)

Reduce ectopic fat
Technology Platform

Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications

Capital Cell - Ministerio de Ciencia e Innovación. Granted 2023
Investment & public funds

Crowdfunding & capital risk.
Plan de recuperación, Transformación y Resilencia.

Pathologies Derived from Fat Accumulation

Increased ectopic fat accumulation:

Fatty liver and NASH

  • Liver fat accumulation, fibrosis and inflammation leading to cirrhosis.
  • Silent disease, low awareness and poor diagnosis.
  • Co-morbidities obesity, diabetes, hyperlipidemia and hypertension.
Cellulite - Subcutaneous fat

Cellulite

  • Undesirable fat deposits in subcutaneous adipocyte.
  • Socially subterfuge disease affecting +80% pot-puberal females.
  • Scarce science-based innovation in the last decade.
Arrow down

Endolipid proposed strategy:

Mimicking
SHBG

Use one of our body endogenous mechanism to reduce fat, fibrosis and inflammation in the liver and the adipose tissue.

Sex Hormone Binding Globulin (SHBG)

Mimicking SHBG, an innovative new strategy to reduce ectopic fat accumulation.

SHBG

Sex Hormone-Binding Globulin

  • Plasma glycoprotein
  • Produced by the liver and secreted Into the blood.
  • Binds sex steroids.
  • Low plasma SHBG levels related to subjects with obesity, fatty liver, type 2 diabetes and PCOS.
SHBG alternative functions
SHBG alternative functions

Lipolysis (1) Lipogenesis (2,3) Fibrosis (4) Inflammation (3,5)
Dr. David M Selva from the VHIR research group is world leader in SHBG biology.

(1) Lipolysis: Sáez-López et al 2020 J Nutr Biochem.
(2) Lipogenesis: Sáez-López et al 2015 and 2017 Endocrinology.
(3) Lipogenesis, Inflammation: Sáez-López et al 2019 JCEM),
(4) Fibrosis: Selva DM et al unpublished.
(5) Inflammation: Yamazaki H et al 2018 Mediators Inflamm.

The ENDOLIPID Technology.
SHBG-mimic Peptides

Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite.
Therapeutic and dermocosmetic applications.

SHBG-mimic: EDL Technology® EDL3D peptide: Innovation in dermocosmetics. EDL6D peptide: Innovation in NASH therapeutics
SHBG reduces liver fat accumulation
SHBG reduces liver fat accumulation
SHBG-mimic: EDL Technology® EDL3D peptide: Innovation in dermocosmetics. EDL6D peptide: Innovation in NASH therapeutics
EDL3D - Cellulite: Reduce subcutaneos fat

Co-development and license to

Nanovex
EDL6D - Fatty liver and Nash: Prevent and treat visceral adiposity

EDL6D is a new peptide that restores
SHBG functions and reduces the main causes of NASH

EDL6D is a new peptide that restores SHBG functions and reduces the main causes of NASH

Peptide EDL6D in vivo Validation

EDL6D is aligned with next generation treatments reducing main causes of NASH

Chart: Steatosis, Fibrosis
Graphic Inflammation

Endolipid (EDL) Peptide Products

Mimicking SHBG, an innovative approach to NASH and cellulite thin pipelines.

Two peptides EDL6D (NASH) is in preclínical development and
EDL81 (Cellulite) is in co-development

ADL6D Nash

EDL6D – NASH.

  • Outstanding efficacy in vivo in obesity,
    NAFLD/NASH and fibrosis mice models.
  • Peptide hits the main causes of the disease
  • New MoA with strong science fundaments
  • Favourable safety profile
EDL81 Cellulite

EDL81 – Cellulite.

  • Strong lipolytic effect in vitro and
    ex vivo in human skin models
  • Peptide in co-development with
    delivery specialist Nanovex”
Nanovex
  • Favourable safety profile
  • New MoA with strong science fundaments

Supported by:

http://Ministerio%20de%20Ciencia%20e%20Innovación%20–%20Financiado%20por%20la%20Unión%20Europea
http://Vall%20d’Hebron%20Institut%20de%20Recerca
http://Instituto%20de%20Salud%20Carlos%20III
http://Genesis%20Ventures

Contact

EndoLipiD Therapeutics

Vall d’Hebrón Institut de Recerca (VHIR)
Laboratori 114 – Edifici Mediterrànea

Passeig de la Vall d’Hebrón 119-129
08035 Barcelona, Spain

Mail: info@endolipid.com